XML 114 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Revenue by Geographical Region (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Total revenue $ 753.2 $ 678.4 $ 690.6
Testing Revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 753.2 678.4 666.4
Hereditary Cancer      
Disaggregation of Revenue [Line Items]      
Total revenue 327.8 305.5 316.3
Tumor Profiling      
Disaggregation of Revenue [Line Items]      
Total revenue 135.6 128.6 120.9
Prenatal      
Disaggregation of Revenue [Line Items]      
Total revenue 151.3 116.4 106.8
Pharmacogenomics      
Disaggregation of Revenue [Line Items]      
Total revenue 138.5 127.6 93.7
Autoimmune      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.3 28.2
Other      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.0 0.5
Other revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.0 24.2
United States      
Disaggregation of Revenue [Line Items]      
Total revenue 671.7 591.5 603.7
United States | Testing Revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 671.7 591.5 579.5
United States | Hereditary Cancer      
Disaggregation of Revenue [Line Items]      
Total revenue 280.5 263.5 271.0
United States | Tumor Profiling      
Disaggregation of Revenue [Line Items]      
Total revenue 102.1 84.5 80.4
United States | Prenatal      
Disaggregation of Revenue [Line Items]      
Total revenue 150.6 115.6 106.2
United States | Pharmacogenomics      
Disaggregation of Revenue [Line Items]      
Total revenue 138.5 127.6 93.7
United States | Autoimmune      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.3 28.2
United States | Other      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.0 0.0
United States | Other revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.0 24.2
Rest of world      
Disaggregation of Revenue [Line Items]      
Total revenue 81.5 86.9 86.9
Rest of world | Testing Revenue      
Disaggregation of Revenue [Line Items]      
Total revenue 81.5 86.9 86.9
Rest of world | Hereditary Cancer      
Disaggregation of Revenue [Line Items]      
Total revenue 47.3 42.0 45.3
Rest of world | Tumor Profiling      
Disaggregation of Revenue [Line Items]      
Total revenue 33.5 44.1 40.5
Rest of world | Prenatal      
Disaggregation of Revenue [Line Items]      
Total revenue 0.7 0.8 0.6
Rest of world | Pharmacogenomics      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.0 0.0
Rest of world | Autoimmune      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.0 0.0
Rest of world | Other      
Disaggregation of Revenue [Line Items]      
Total revenue 0.0 0.0 0.5
Rest of world | Other revenue      
Disaggregation of Revenue [Line Items]      
Total revenue $ 0.0 $ 0.0 $ 0.0